An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

• Sponsor: Recordati Rare Diseases (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT05040178
• Collaborator: Target PharmaSolutions, Inc. (Industry)
• Enrollment: 20
• Locations: 2
• Anticipated Duration (Months): 120
• Patients Per Site: 10
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.

Condition or Disease	Intervention/Treatment	Phase
Hyperammonemia; Methylmalonic Acidemia; Propionic Acidemia	Drug: Carglumic Acid

Detailed Description

This study is being conducted to obtain short-term and long-term clinical safety information from adult and pediatric patients treated for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). This is an observational/non-interventional study. Patients will be treated per the prescribing information and routine medical practice.

Only available data will be collected as part of the study including developmental outcomes, details of treatment with Carbaglu® and other treatments for hyperammonemia including dietary and protein management, plasma ammonia levels, pregnancy and maternal complications, adverse effects on the developing fetus and neonate, adverse effects on the infant through first year of life.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 20 participants
• Observational Model: Cohort
• Time Perspective: Other
• Official Title: A Non-Interventional Post-Authorization Safety Study (PASS) of Carbaglu® for the Treatment of Hyperammonemia Due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) in Adult and Pediatric Patient Populations
• Anticipated Study Start Date: Jun 30, 2022
• Anticipated Primary Completion Date: Jun 30, 2032
• Anticipated Study Completion Date: Jun 30, 2032

Arms and Interventions

Arm	Intervention/Treatment
Male and Female Adult and Pediatric Participants Patients treated with Carbaglu for the treatment for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)	Drug: Carglumic Acid; Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.; Other Names: Carbaglu®

Outcome Measures

Primary Outcome Measures

1. Effects of Carbaglu® on plasma ammonia levels [Patients treated with Carbaglu® will be managed chronically (out-patient) or acutely (hospital in-patient). In both cases, data will be collected for approximately 1 year following discontinuation of Carbaglu treatment.]

   Multiple plasma ammonia levels will be collected only during treatment with Carbaglu® according to prescribing information and routine medical practice in terms of visit frequency.

2. Adverse Event frequency and severity [Patients treated with Carbaglu® will be managed chronically (out-patient) or acutely (hospital in-patient). In both cases, data will be collected for approximately 1 year following discontinuation of Carbaglu treatment.]

   Any Carbaglu® related adverse events will be be collected and reported

Secondary Outcome Measures

1. Fetal Outcomes and Pregnancy Outcomes [Collection of pregnancy information for patients who becomes pregnant while participating in the trial or at time of enrollment. Pregnancy reports and reports involving neonates and infants up to 1 year of age must be reported to RRD Pharmacovigilance.]

   Pregnancy risks including maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant (through the first year of life).

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Provision of signed and dated informed consent/assent form

2. Prescribed and treated with Carbaglu®

3. Have an established diagnosis of PA or MMA defined as follows:

• Diagnosed with PA by semi quantitative urine organic acid analysis, defined as presence of elevated methylcitric acid and normal methylmalonic acid levels and no evidence of biotin related disorders in the organic acid analysis; OR

• Diagnosed with MMA by semi quantitative urine organic acid analysis, defined as elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis (vitamin B12 dependency is defined by documented vitamin B12 responsiveness).

AND/OR

• Confirmation by molecular genetic testing

Exclusion Criteria:

• None

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Children's National Medical Center	Washington	District of Columbia	United States	20010
2	Riley Children's Hospital	Indianapolis	Indiana	United States	46202

Sponsors and Collaborators

• Recordati Rare Diseases
• Target PharmaSolutions, Inc.

Investigators

• Study Director: William Ludlum, MD, Recordati Rare Diseases Inc.
• Principal Investigator: Nicholas Ah Mew, MD, Children's National Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Recordati Rare Diseases
• ClinicalTrials.gov Identifier: NCT05040178
• Other Study ID Numbers: CARBAGLU-RRDUS-PASS-0573
• First Posted: Sep 10, 2021
• Last Update Posted: Jul 1, 2022
• Last Verified: Jun 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Recordati Rare Diseases: PA & MMA
• Additional relevant MeSH terms: Amino Acid Metabolism, Inborn Errors; Propionic Acidemia; Acidosis; Hyperammonemia

Study Results

No Results Posted as of Jul 1, 2022